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Thymidine phosphorylase (TP) catalyses the reversible synthesis
of thymidine, and inorganic phosphate, from thymine using
deoxyribose-1-phosphate as a co-substrate. TP is present in a wide
range of normal human tissues (Fox et al, 1995), with elevated
expression in many tumours including breast, lung, bladder,
colorectal, and gastric cancers (Fox et al, 1996; Giatromanolaki et
al, 1997; O’Brien et al, 1996; Takahashi et al, 1998; Takebayashi
et al, 1996; Yoshikawa et al, 1999). TP is important in tumour
angiogenesis (Moghaddam and Bicknell, 1992; Moghaddam et al,
1995) and elevated levels in cancer cells can be exploited in
cytotoxic chemotherapy for the activation of the fluoropyrimidine,
5-fluorouracil (5-FU).
TP converts 5-FU to 2¢-deoxy-5-fluorouridine (FUdR) which in
turn is metabolized by thymidine kinase (TK) to 5-fluoro-
deoxyuridine monophosphate (FdUMP). FdUMP forms a ternary
complex with 5,10 methylene-tetrahydrofolate (5,10-CH2-THF)
and thymidylate synthase (TS) leading to defective DNA synthesis
and repair. Other biochemical pathways involving TS include
metabolism of 5-FU to 5-fluorouridine diphosphate (FUDP),
which interferes with glycosylation of proteins and lipids, and
5-fluorouridine triphosphate (FUTP) which is incorporated into
RNA. Attempts to further enhance the cytotoxicity of 5-FU in
clinical trials have developed from in vitro models that demon-
strate enhanced activity following biochemical modulation with
agents such as folinic acid (calcium folinate) and interferon
(Moran and Scanlon, 1991; Wadler et al, 1990b).
The addition of folinic acid to 5-FU-containing schedules
enhances the binding of FdUMP to the ternary complex leading to
greater cytotoxicity. Similarly, in vitro interferon a (IFNa)
increases TP levels with a corresponding increase in FdUMP
formation, and causes single- and double-strand DNA breaks in
colon carcinoma cell lines (Houghton et al, 1993; Schwartz et al,
1994; 1995; Wadler et al, 1990b, 1996). Modulation of 5-FU
metabolism by folinic acid or IFNa alone has been assessed in a
number of clinical trials in patients with colorectal cancer with
evidence for enhanced clinical response (ACCM-AP, 1992; Corfu-
A Study Group, 1995; Ragnhammar et al, 1995; Wadler et al,
1991). However, double modulation of 5-FU with folinic acid and
IFNa has not enhanced efficacy compared to 5-FU and folinic
acid alone, but has increased toxicity (Kosmidis et al, 1996;
Seymour et al, 1996; Woolmark et al, 1998). A wide range of
schedules have been studied, but most trials have not used
biochemical or pharmacological markers to assess the optimal
combination in terms of dose and frequency of administration of
Induction of thymidine phosphorylase as a
pharmacodynamic end-point in patients with advanced
carcinoma treated with 5-fluorouracil, folinic acid and
interferon alpha
JP Braybrooke1, DJ Propper1, KJ O’Byrne1, MI Koukourakis2, AV Patterson1, S Houlbrook1, SD Love1, S Varcoe1,
M Taylor1, TS Ganesan1, DC Talbot1 and AL Harris1
1ICRF Medical Oncology Unit, Churchill Hospital, Oxford, OX3 7LJ, UK; 2Department of Radiotherapy and Oncology, University Hospital of Iraklion,
Iraklion 71110, Crete, Greece
Summary Thymidine phosphorylase (TP) is an essential enzyme for the biochemical activation of 5-fluorouracil (5-FU). Interferon
upregulates TP in vivo, although the dose and schedule of interferon for optimal biomodulation of 5-FU is not known. In this study, TP activity
was measured in peripheral blood lymphocytes (PBLs) from patients with advanced carcinoma receiving treatment with 5-FU and folinic acid.
Cohorts of patients were treated with interferon alpha (IFNa), immediately prior to 5-FU/folinic acid, at doses of 3 MIU m–2, 9 MIU m–2 and
18 MIUm–2. IFNa was administered on day 0 cycle two, day –1 and day 0 cycle three and day –2, day –1 and day 0 cycle four. A fourth cohort
was treated with IFNa 9 MIU m–2 three times per week from cycle 2 onwards. Twenty-one patients were entered into the study with
19 evaluable for response. Six patients (32%) had stable disease and 13 (68%) progressive disease. There were no grade-IV toxicities. TP
activity was detected in PBLs from all patients with wide interpatient variability in constitutive TP activity prior to chemotherapy, and in
response to IFNa. 5-FU/folinic acid alone did not induce TP activity but a single dose of IFNa led to upregulation of TP within 2 h of
administration with a further increase by 24 h (signed rank test, P = 0.006). TP activity remained elevated for at least 13 days (signed rank
test, P = 0.02). There were no significant differences in TP activity between schedules or with additional doses of IFNa. A single dose of IFNa
as low as 3 MIU m–2 can cause sustained elevation of PBL TP activity in vivo indicating that biochemical markers are important
pharmacodynamic endpoints for developing optimal schedules of IFNa for biomodulation of 5-FU. © 2000 Cancer Research Campaign
Key words: thymidine phosphorylase; interferon alpha; 5-fluorouracil; folinic acid
219
Received 6 October 1999
Revised 2 March 2000
Accepted 10 March 2000
Correspondence to: AL Harris
British Journal of Cancer (2000) 83(2), 219–224
© 2000 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1230, available online at http://www.idealibrary.com on IFNa in conjunction with 5-FU and folinic acid (Wadler et al,
1990a).
IFNa does not directly modify 5-FU pharmacokinetics in vivo
(Seymour et al, 1994b) but induces TP both in vitro (Schwartz
et al, 1995) and in vivo. Makower et al (1997) measured TP
mRNA and protein levels in peripheral blood lymphocytes from
patients with advanced malignancy receiving treatment with 5-FU
and either IFNa or b at doses of 5–10 MIU. Fifteen of 21 (71%)
patients exhibited an increase in TP protein levels of two-fold or
greater after a single dose of IFNa or  b, with elevated levels
persisting for up to 48 h. There was a corresponding rise in TP
mRNA levels in these patients demonstrating that one of the
actions of interferon is to induce TP by regulation of the level of
mRNA expression.
The effect of different doses and schedules of IFNa on TP
induction and the subsequent effect on both 5-FU activation and
tumour angiogenesis in vivo is not known. In this study, in order to
try and develop a rational basis for 5-FU modulation, we assess the
effect of double biomodulation of a standard schedule of 5-FU
with folinic acid and IFNa on peripheral blood lymphocyte TP
activity. The dose of interferon, and schedule of administration,
was escalated during the study in order to evaluate which dose and
schedule of IFNa gives the highest TP induction for longest. We
demonstrate that 5-FU and folinic acid alone do not increase TP
protein activity but that a single dose of IFNa as low as 3 MIU m–2
rapidly induces TP and that this can remain elevated for up to
13 days.
PATIENTS AND METHODS
Patients
Patients with progressive advanced carcinoma suitable for treat-
ment with 5-FU/folinic acid or those with carcinoma refractory to
conventional treatment schedules were entered into the study.
Eligibility criteria included histological or cytological proof of
diagnosis, age over 18 years, written informed consent, measur-
able or evaluable disease and adequate bone marrow, renal and
hepatic function. Patients were excluded if they had received
chemotherapy within the past 4 weeks, had concurrent infection or
a history of autoimmune disease or major psychiatric disorder. All
patients gave written informed consent and the trial was conducted
with the approval of the Central Oxford Research Ethics
Committee.
Drug administration
5-FU and folinic acid were administered every 2 weeks in hospital
using a modified De-Gramont schedule (De Gramont et al, 1988) to
a maximum of eight cycles. Folinic acid 200 mg m–2 in 250 ml 0.9%
saline was given as an i.v. infusion over 2 h on day 0, immediately
followed by 5-FU 400 mg m–2 in 100 ml 0.9% saline i.v. over 10
min with a subsequent continuous i.v. infusion of 5-FU 400 mg m–2
in 1l 0.9% saline over 22 h. This was repeated on day 1. IFNa
(Roferon-A, Roche, Welwyn Garden City, UK) was administered
s.c. prior to each administration of 5FU/folinic acid on cycle two
and subsequent cycles. There was a within-patient and between-
patient dose escalation of IFNa. Patients received no IFNa on cycle
one, treatment with IFNa on day 0 of cycle two, day –1 and day 0 of
cycle three and day –2, day –1 and day 0 of cycle four. Cohort one
was treated with IFNa 3 million international units (MIU) m–2 at
each dose, cohort two with 9 MIU m–2 and cohort three with 18 MIU
m–2. Cohort four received a more conventional schedule of IFNa
administered at 9 MIU m–2 on day 0, 2 and 4 during the week that
they were being treated with 5FU/folinic acid. This schedule was
given from cycle two of treatment with no further escalation in dose
for cycles three and four. IFNa, where possible, was administered at
the same time each day to minimize the possibility of error caused
by circadian variability in TP activity.
Antiemetic prophylaxis consisted of metoclopramide 10 mg
q.d.s/p.r.n. Patients who experienced fever following IFNa were
treated with paracetamol 1 g q.d.s. and, if fever remained uncon-
trolled naproxen 500 mg b.d. This was continued as prophylaxis in
these patients prior to further interferon. All other concurrent
medication was permitted with the exception of steroids unless the
patient remained on a stable dose throughout the cycles of treat-
ment.
Treatment was delayed for 1 week in patients with absolute
neutrophil count < 1.5 ´ 109 l–1 or platelet count < 100 ´ 109 l–1.
Treatment was also delayed for any grade III/IV non-haematolog-
ical toxicity until that toxicity had resolved to grade I or less. The
dose of IFNa was reduced to the treatment level in the previous
cohort in patients who did not tolerate the prescribed dose or
whose treatment was delayed for more than 1 week. Toxicity was
graded according to WHO criteria and disease response was eval-
uated clinically and by CT scan after four courses and at the
completion of treatment. Standard WHO criteria for objective
tumour response assessment were employed.
Blood samples
Venous blood samples were taken during the first four cycles of
the study for lymphocyte separation in order to monitor the effect
of treatment on TP levels in peripheral blood lymphocytes (PBL).
For cohorts one, two and three, on cycle one, blood was taken
prior to treatment (day 0) and on days 1, 2 and 7. For subsequent
cycles samples were taken prior to each dose of IFNa and on days
0, 1, 2 and 7. After the first dose of IFNa on cycle two only, an
additional sample was taken at +2 h. For cohort four, on the
conventional schedule of IFNa, blood was taken on days 0, 2 and
7 only.
10 ml venous blood samples were collected at each time point
into glass ‘vacutainer’ tubes (Becton Dickinson, New York, USA)
containing EDTA and placed on ice before processing.
Lymphocytes were separated over ‘lymphoprep’ (Nicomed,
Majorstua, Norway) under aseptic conditions and centrifuged at
1500 g for 20 min. The plasma supernatant was aspirated and the
lymphocyte pellet was frozen at –70°C until analysis.
Biochemical evaluation of thymidine phosphorylase
Lymphocyte pellets were thawed, washed and re-suspended in
1 ml Tris-HCl buffer (50 mM Tris-CL, 150 mM NaCl, 0.05 mM
DTT, 0.05 mM PMSF, pH 7.4) at 4°C. Cells were sonicated on ice
before centrifuging at 10 000 g for 30 min. The supernatant was
harvested and stored in liquid nitrogen until analysis. Total protein
content for each of the cell lysates was determined by the Bradford
assay (Bio-Rad, Hemel Hempstead, UK) and quantified using a
BSA standard (Sigma, Poole, UK, 1 mg ml–1).
Thymidine phosphorylase activity assays were performed by
spectrophotometric monitoring and have been described previ-
ously (Patterson et al, 1995). Briefly, 20 mg of lymphocyte
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PO4, pH 7.4 in a final volume of 300 ml for 16 h at 37°C. The reac-
tion was terminated by the addition of 700 ml of ice-cold 0.5 M
NaOH to produce a final solution pH of 13.3. The formation of
thymine from thymidine was determined by measuring absorbance
in a spectrophotometer at 300 nm. Total thymine formation was
quantified against a known standard (range 0.1–1 mM) and
activity expressed as nmol thymine released hr–1 mg–1 protein.
There was no significant difference between repeat assays of the
same sample (paired t = test, P = 0.9, n = 15).
Correlation of TP protein levels with TP protein activity
PBLs collected from five patients in the study were assayed for TP
activity as described above and for total TP protein levels deter-
mined by protein immunoblots using the anti-TP antibody PG44c
(kindly supplied by Dr R Bicknell, ICRF) (Moghaddam et al,
1995). Total TP protein levels at each time-point were assessed by
measuring absorbance on the Bio-imager (Milligen/Biosearch,
Millipore). There was a strong positive correlation between the
two techniques (Spearmans correlation coefficient, rho = 0.83,
P < 0.001) and all other samples were therefore only analysed for
TP activity.
Statistical methods
Using the method of summary measures (Matthews et al, 1990),
the area under the TP curve (AUC), adjusting for baseline TP
(where adjustment is value minus single pretreatment TP value),
was chosen for analysis in order to evaluate which dose (cohort)
and which schedule (cycle) of IFNa gives the highest TP induction
for longest. Since the data did not differ appreciably from indepen-
dence, ANOVA was the final method used to predict the optimal
dose and schedule of IFNa for TP induction.
Initially, to assess the effect of 5FU/folinic acid alone, a
Wilcoxon signed rank test was used to compare matched pairs of
TP values on day 0 with days 1, 2, 7 and 13 of cycle one, including
patients from all four cohorts. To consider the effect of a single
dose of interferon on TP levels signed rank tests were used for
paired values for cycle two, cohorts one–three, for day 0 and data
from day 0 + 2 h, day 1, day 2, day 7 and day –1 of cycle three. The
question of whether interferon had a carryover effect on baseline
TP levels between cycles was compared using Friedman’s non
parametric two-way analysis of variance.
When using the raw TP values, non-parametric tests were
necessary because the data did not show a normal distribution.
RESULTS
Twenty-one patients were entered into the study (median age 58
years, range 46–72). Sites of primary tumour included renal (five
patients), colorectal (three), breast (three), unknown primary
adenocarcinoma (three), pancreas (two), gastric, bladder, cholan-
giocarcinoma, carcinoid and lung adenocarcinoma (one each).
Seven patients were previously untreated with chemotherapy and
ten patients had received one prior chemotherapy schedule, of
whom two had received 5-FU. Four patients had previously
received two chemotherapy schedules.
Thymidine phosphorylase activity
TP activity was detected in PBLs in all patients with wide interpa-
tient variability in the constitutive level prior to any chemotherapy
(median = 329.2 nmol thymine released hr–1 mg–1 protein, range
187–587, n = 19). There was no significant increase in TP activity
during cycle one when patients were treated with 5-FU/folinic acid
alone (signed rank test, P > 0.05 in all cases, n = 19).
Immediate effect of IFNa
The effect of the first dose of IFNa on lymphocyte TP activity in
patients from cohorts one to three was evaluated in cycle two by
paired analysis of pre-IFNa samples with those taken at day
0 + 2 h, day 1, day 2, day 7 and day 13. An immediate effect of
IFNa on TP levels was observed at 2 h (median increase
= 41.7 nmol thymine released h–1 mg–1 protein, signed rank test,
P = 0.04, n = 13), with a further increase in TP activity by 24 h
(median increase = 106.8 nmol thymine released h–1 mg–1 protein,
signed rank test, P = 0.006, n = 14). TP activity remained elevated
compared to baseline at day 7 of cycle two (median increase =
90.45 nmol thymine released h–1 mg–1 protein, signed rank test,
P = 0.003, n = 14) with persisting upregulation at day 13 (median
increase 134.6 nmol thymine released h–1 mg–1 protein, signed
rank test, P = 0.02; n = 12) (Figure 1). There was considerable
variation between patients in the response of their PBL TP activity
to the first dose of IFNa. Nine out of 14 patients (64%) sampled
24 h after the first dose of IFNa, had a greater than 20% increase
in TP activity with three (22%) showing no change and two (14%)
a decrease. Of the nine patients whose TP activity was elevated 24
h after a single dose of IFNa, it remained elevated for up to eight
days in seven patients (78%) and was still greater than 20% above
baseline in five out of eight (62.5%) of those patients assessed at
day 13. Figure 2 shows the variation in PBL TP activity in one
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Figure 1 Box whisker plot showing median induction of PBL TP activity in
cycle two following a single dose of IFNa for cohorts one–three. PBLs were
collected prior to IFNa on day 0 and then at day 0 + 2 h, day 1, day 2, day 7,
and day 13. 5-FU/folinic acid was commenced immediately after the IFNa on
day 0. The ‘box’ extends to the interquartile range and the ‘whiskers’ to 1.5
times the interquartile range. There was a significant induction of TP activity,
compared to cycle two day 0, within 2 h of IFNa with a further increase by 
24 h. TP activity remained elevated for at least 13 days.patient who demonstrated an increase in TP activity with doses
of IFNa.
Duration of effect of IFNa
The prolonged effects of a single dose of IFNa on TP activity for
the 14 days between chemotherapy cycles was evaluated by
comparing the baseline TP activity prior to cycle two with baseline
TP activity in cycle three and cycle four (Figure 3). In cohorts one
to three, analysed together, there was an increase in baseline TP
activity prior to cycle three (median = 415.3 nmol thymine
released h–1 mg–1 protein, range 272–1069, Friedman’s non para-
metric, P = 0.009; n = 14). There was no further increase in base-
line TP activity at cycle four (median = 349.6 nmol thymine
released h–1 mg–1 protein, range 296–806, n = 14).
Dose response of IFNa
One of the aims of this study was to assess which of the four
schedules of IFNa used could be recommended for larger studies
based on biochemical analysis of TP activity. The AUC of TP
activity, adjusting for baseline, did not show a statistically
significant difference between doses or between cycles (ANOVA,
P > 0.1 in all cases). Similarly there was no significant difference
in TP induction by the same total dose of IFNa administered by
different schedules, e.g. 9 MIU/m2 as a single dose compared with
3 ´ 3 MIU m–2 (ANOVA, P = 0.9).
Toxicity
A total of 85 cycles of chemotherapy were administered with a
median of four per patient. Two patients received the maximum of
eight cycles and two discontinued after only one cycle. The main
toxicities observed were diarrhoea (WHO grade 2 or 3, n= 5), nausea
and vomiting (n= 6), pyrexia (n= 12), mucositis (n= 8), neutropenia
(n = 4) and thrombocytopenia Thrombocytopenia was only observed
in patients in cohort three (two patients grade I, one grade II) and
cohort four (one grade III). There were no grade IV toxicities.
Four patients discontinued treatment due to toxicity (one patient
in cohort two after five cycles due to IFNa-induced pyrexia, one
patient in cohort three after one cycle with persistent neutropenia
on 5-FU and folinic acid alone, two patients in cohort four after
four cycles, one with neutropenia and the other with persistent
diarrhoea). Two patients required treatment to be delayed for 1
week and two patients had a dose reduction in IFNa due to haema-
tological toxicity. There was no association between toxicity and
TP induction for individual patients.
Response
Nineteen patients were evaluable for response (one discontinued
after one cycle due to toxicity and one withdrew from the study
after one cycle). There were no complete or partial responses. Six
patients (32%) had stable disease (SD) for at least 3 months. These
included five patients who were previously untreated with
chemotherapy (tumour types: colorectal, pancreas, cholangiocar-
cinoma, carcinoid and unknown primary adenocarcinoma), and
one patient with gastric carcinoma previously treated with mito-
mycin C and oral etoposide. Thirteen patients had progressive
disease (PD). There was no significant difference in TP levels
between patients with SD or PD.
DISCUSSION
Thymidine phosphorylase (TP) is an important enzyme for the
metabolic activation of 5-FU. TP can be upregulated by IFNa,
although clinical trials adding IFNa to schedules of 5FU and
folinic acid have not shown improved tumour responses
(Kosmidis  et al, 1996; Seymour et al, 1996). In order to evaluate
the effect of IFNa in vivo we have treated patients with advanced
carcinomas with a standard schedule of 5-FU and folinic acid and
analysed the effect of different doses and schedules of IFNa on TP
activity in PBLs as a pharmacodynamic end-point.
222 JP Braybrooke et al
British Journal of Cancer (2000) 83(2), 219–224 © 2000 Cancer Research Campaign
T
h
y
m
i
n
e
 
r
e
l
e
a
s
e
d
 
h
–
1
 
m
g
–
1
 
p
r
o
t
e
i
n
 
(
n
m
o
l
)
600
500
400
300
200
100
0
Cycle one Cycle two Cycle three Cycle four
d0+2hd1 d2 d7 d0 d1 d2 d7 d0 d1 d-1 d2 d7 d0 d-1 d1 d2 d-2 d7
Interferon 9 MIU m–2
Sample date (days)
Figure 2 Change in PBL TP activity in a single patient treated with a
standard schedule of 5-FU/folinic acid and IFNa 9 MIU m–2 from cycle two
onwards. The days of administration of IFNa are indicated by arrows. Data
for PBL TP activity is expressed as thymine released h–1 mg–1 protein (nmol)
(Y-axis). X-axis = sample date and cycle.
1000
750
500
250
0
Cycle one Cycle two
P
B
L
 
T
P
 
a
c
t
i
v
i
t
y
 
(
n
m
o
l
 
t
h
y
m
i
n
e
 
r
e
l
e
a
s
e
d
 
h
–
1
 
m
g
–
1
 
p
r
o
t
e
i
n
)
Cycle three Cycle four
IFNa IFNa IFNa
d
0
d
0
+
2
h
d
1
d
2
d
7
d
0
d
1
d
2
d
7
d
0
d
1
d
-
1
d
2
d
7
d
0
d
-
1
d
1
d
2
d
-
2
d
7
Figure 3 Effect of IFNa on PBL TP activity (all cohorts). IFNa was
administered on day 0 cycle two, day –1, day 0 cycle three and day –2,
day –1, day 0 cycle four) cohorts one–three. Cohort four received IFNa days
0, 2 and 4 from cycle two onwards. PBL TP activity, expressed as thymine
released h–1 mg–1 protein (nmol), is pooled for all cohorts and expressed as a
mean for all samples (Y-axis). The days of administration of IFNa are
indicated by arrows. Bars = SEM. X-axis = sample date and cycle.We have shown that there is considerable heterogeneity in
constitutive PBL TP activity in this group of cancer patients and
that treatment with 5-FU and folinic acid alone did not increase TP
activity. Addition of a single dose of IFNa to this schedule signifi-
cantly upregulates PBL TP protein activity within 2 h of adminis-
tration with a 20% or greater increase in activity in most patients
(64%) by 24 h, confirming this as one of the metabolic effects of
IFNa in vivo. The level of TP induction was less than previously
reported (Makower et al, 1997) which may reflect the different
assays used. Importantly, the data also demonstrates that, in a
significant number of patients (22%), TP activity is not increased
by IFNa and in some (14%) it decreases. PBL TP activity,
following a single dose of IFNa, was upregulated for at least 8
days and this can be sustained for up to 14 days in the majority of
patients (62.5%) who show an initial response. Additional doses of
IFNa did not significantly increase TP activity or produce toler-
ance (Figure 3). Similarly, higher doses of IFNa did not lead to a
statistically significant greater level of TP induction.
Induction of TP in vivo should enhance 5-FU cytotoxicity as
well as potentially enhancing the efficacy of pro-drugs of 5-FU
such as capecitabine. In this study many of the patients were
heavily pre-treated or had tumours resistant to conventional cyto-
toxic therapy. There were no partial or complete responses,
although 32% of patients had stable disease for at least 3 months
after completion of treatment. The addition of IFNa to the treat-
ment was generally well tolerated with no grade IV toxicities. PBL
TP levels in individual patients were not significantly associated
with tumour response or toxicity. TP is important in tumour angio-
genesis as well as 5-FU activation. Induction of TP should there-
fore be considered with caution because of evidence that elevated
levels may be associated with a worse outcome in some tumour
types (Yoshikawa et al, 1999). Whilst PBL TP activity was
measured for ease of sampling, the direct effect of IFNa on tumour
cells in vivo is not known. Future studies are needed to correlate
TP activity in fine-needle aspirates from accessible cancers with
PBL TP activity.
In randomized studies the addition of IFNa, at a dose of 5 and 6
MIU on alternate days, to schedules of 5-FU and folinic acid, does
not improve responses. This dose and schedule of IFNa, based on
phase I studies, adversely effects the quality of life of patients
receiving treatment (Seymour et al, 1994a; Wadler et al, 1990a).
We attempted to address whether there was biological evidence in
vivo for using alternate day schedules of IFNa compared to those
with higher and lower doses of interferon administered at different
frequencies. In the four cohort groups treated there was no consis-
tent pattern for TP activity between cohorts or across cycles. While
the numbers of patients treated were small, there was no sugges-
tion that treating patients with IFNa 9 MIU/m2 three times per
week led to enhanced TP induction compared with a single dose of
IFNa every 14 days. Equally, the same total dose of interferon
administered by different schedules did not significantly affect TP
induction.
The heterogeneity in constitutive TP activity and the response of
individual patients to IFNa meant that there were no statistically
significant differences in the level of TP induction between
cohorts. A single dose of IFNa, as low as 3 MIU/m2 before each
cycle of 5-FU and folinic acid, led to a rapid and sustained rise in
PBL TP activity in some patients, suggesting that this dose may be
as biologically active and better tolerated than more intensive
schedules. In other patients there was no induction of TP activity
with IFNa and in a small number there appeared to be a reduction
in activity. The mechanism of action of IFNa in vivo is not fully
understood. The effect on other cytokines, as well as anti-angio-
genic actions, will also be important in clinical efficacy.
This study indicates that measurement of TP activity in PBLs
from patients receiving chemotherapy is possible and that there is
considerable heterogeneity in both baseline activity and in
response to IFNa. The variability between individuals in their
biological response to IFNa may provide an indicator for which
patients are likely to benefit from the addition of IFNa to a stan-
dard schedule of 5-FU and folinic acid with implications for treat-
ment in terms of toxicity and cost. The use of IFNa at a maximal
tolerated dose may not be the most biologically active schedule in
vivo with doses as low as 3 MIU/m2 every 2 weeks, leading to
rapid and sustained induction of TP. The design of larger studies
modulating 5-FU with IFNa should therefore incorporate biolog-
ical markers such as TP activity as a pharmacodynamic end-point.
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